Leeza Shrestha
Overview
Explore the profile of Leeza Shrestha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dahal A, Parajuli P, Singh S, Shrestha L, Sonju J, Shrestha P, et al.
J Pharmacol Sci
. 2022 May;
149(3):124-138.
PMID: 35641025
Protein-protein interactions (PPI) of co-stimulatory molecules CD2-CD58 are important in the early stage of an immune response, and increased expression of these co-stimulatory molecules is observed in the synovial region...
2.
Naik H, Sonju J, Singh S, Chatzistamou I, Shrestha L, Gauthier T, et al.
Pharmaceuticals (Basel)
. 2021 Apr;
14(3).
PMID: 33800723
The therapeutic index of chemotherapeutic agents can be improved by the use of nano-carrier-mediated chemotherapeutic delivery. Ligand-targeted drug delivery can be used to achieve selective and specific delivery of chemotherapeutic...
3.
Parajuli P, Sable R, Shrestha L, Dahal A, Gauthier T, Taneja V, et al.
Chem Biol Drug Des
. 2020 Sep;
97(3):607-627.
PMID: 32946175
Peptides were designed to inhibit the protein-protein interaction of CD2 and CD58 to modulate the immune response. This work involved the design and synthesis of eight different peptides by replacing...
4.
Shrestha L, Singh S, Parajuli P, Dahal A, Mattheolabakis G, Meyer S, et al.
J Cancer
. 2020 Sep;
11(20):5982-5999.
PMID: 32922539
Studies related to lung cancer have shown a link between human epidermal growth factor receptor-2 (HER2) expression and poor prognosis in patients with non-small cell lung cancer (NSCLC). HER2 overexpression...
5.
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh S, Dahal A, Shrestha L, Jois S
Curr Med Chem
. 2019 Mar;
27(32):5274-5316.
PMID: 30854949
Eighty-five percent of patients with lung cancer present with Non-small Cell Lung Cancer (NSCLC). Targeted therapy approaches are promising treatments for lung cancer. However, despite the development of targeted therapies...